Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Rescue Treatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing
NCT07533422Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of vonoprazan, amoxicillin, clarithromycin, levofloxacin and tetracycline in Helicobacter pylori infection (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Helicobacter pylori eradication rate at 6 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillinclarithromycinlevofloxacintetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07533422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533422.